Neonatal and obstetrical outcomes of pregnancies in systemic lupus erythematosus

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objectives: Systemic lupus erythematous (SLE) is a chronic autoimmune disease that affects women primarily of childbearing age. The objective of this study was to determine the neonatal and maternal outcomes of pregnancies in SLE patients compared to pregnancies in healthy controls. Methods: We conducted a retrospective cohort study in a tertiary care hospital in Oman between January 2007 and December 2013. We analyzed 147 pregnancies and compared 56 (38.0%) pregnancies in women with SLE with 91 (61.9%) pregnancies in healthy control women. Disease activity was determined using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). Results: The mean age of the cohort was 30.0±5.0 years ranging from 19 to 44 years old. Patients with SLE were treated with hydroxychloroquine (n = 41; 73.2%), prednisolone (n = 38; 67.8%), and azathioprine (n = 17; 30.3%). There was no disease activity in 39.2% (n = 22) of patients while 41.0% (n = 23), 12.5% (n = 7), and 7.1% (n = 4) had mild (SLEDAI 1–5), moderate (SLEDAI 6–10), and severe (SLEDAI ≥ 11) disease activity, respectively, at onset of pregnancy. Pregnancies in patients with SLE were associated with higher abortions (42.8% vs. 15.3%; p < 0.001), gestational diabetes (28.3% vs. 10.2%; p = 0.004), polyhydramnios (7.1% vs. 0.0%; p = 0.020), previous preterm pregnancies (8.9% vs. 1.0%; p = 0.030), and intrauterine growth retardation (21.4% vs. 0.0%; p < 0.001) when compared to pregnancies in healthy control women. Furthermore, the neonates born to mothers with SLE were more likely to be preterm (28.5% vs. 1.0%; p < 0.001), have a low birth weight (< 2 500 g) (32.1% vs. 1.0%; p < 0.001), and were associated with stillbirth (7.1% vs. 0.0%; p = 0.010) when compared to neonates born to healthy control mothers. Conclusions: Pregnancies in women with SLE were associated with higher neonatal and maternal complications. Therefore, pregnant women with SLE should have their pregnancy accurately planned, monitored, and managed according to a multidisciplinary treatment schedule.

Original languageEnglish
Pages (from-to)15-21
Number of pages7
JournalOman Medical Journal
Volume33
Issue number1
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Pregnancy Outcome
Systemic Lupus Erythematosus
Pregnancy
Mothers
Newborn Infant
Oman
Hydroxychloroquine
Polyhydramnios
Stillbirth
Gestational Diabetes
Fetal Growth Retardation
Azathioprine
Family Planning Services
Low Birth Weight Infant
Tertiary Healthcare
Prednisolone
Tertiary Care Centers
Autoimmune Diseases
Pregnant Women
Appointments and Schedules

Keywords

  • Intrauterine growth retardation
  • Neonatal systemic lupus erythematosus
  • Oman
  • Premature infant

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Neonatal and obstetrical outcomes of pregnancies in systemic lupus erythematosus. / Abdwani, Reem; Al Shaqsi, Laila; Al-Zakwani, Ibrahim.

In: Oman Medical Journal, Vol. 33, No. 1, 01.01.2018, p. 15-21.

Research output: Contribution to journalArticle

@article{f9db09aad9c94693bab9dde0af2d0b54,
title = "Neonatal and obstetrical outcomes of pregnancies in systemic lupus erythematosus",
abstract = "Objectives: Systemic lupus erythematous (SLE) is a chronic autoimmune disease that affects women primarily of childbearing age. The objective of this study was to determine the neonatal and maternal outcomes of pregnancies in SLE patients compared to pregnancies in healthy controls. Methods: We conducted a retrospective cohort study in a tertiary care hospital in Oman between January 2007 and December 2013. We analyzed 147 pregnancies and compared 56 (38.0{\%}) pregnancies in women with SLE with 91 (61.9{\%}) pregnancies in healthy control women. Disease activity was determined using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). Results: The mean age of the cohort was 30.0±5.0 years ranging from 19 to 44 years old. Patients with SLE were treated with hydroxychloroquine (n = 41; 73.2{\%}), prednisolone (n = 38; 67.8{\%}), and azathioprine (n = 17; 30.3{\%}). There was no disease activity in 39.2{\%} (n = 22) of patients while 41.0{\%} (n = 23), 12.5{\%} (n = 7), and 7.1{\%} (n = 4) had mild (SLEDAI 1–5), moderate (SLEDAI 6–10), and severe (SLEDAI ≥ 11) disease activity, respectively, at onset of pregnancy. Pregnancies in patients with SLE were associated with higher abortions (42.8{\%} vs. 15.3{\%}; p < 0.001), gestational diabetes (28.3{\%} vs. 10.2{\%}; p = 0.004), polyhydramnios (7.1{\%} vs. 0.0{\%}; p = 0.020), previous preterm pregnancies (8.9{\%} vs. 1.0{\%}; p = 0.030), and intrauterine growth retardation (21.4{\%} vs. 0.0{\%}; p < 0.001) when compared to pregnancies in healthy control women. Furthermore, the neonates born to mothers with SLE were more likely to be preterm (28.5{\%} vs. 1.0{\%}; p < 0.001), have a low birth weight (< 2 500 g) (32.1{\%} vs. 1.0{\%}; p < 0.001), and were associated with stillbirth (7.1{\%} vs. 0.0{\%}; p = 0.010) when compared to neonates born to healthy control mothers. Conclusions: Pregnancies in women with SLE were associated with higher neonatal and maternal complications. Therefore, pregnant women with SLE should have their pregnancy accurately planned, monitored, and managed according to a multidisciplinary treatment schedule.",
keywords = "Intrauterine growth retardation, Neonatal systemic lupus erythematosus, Oman, Premature infant",
author = "Reem Abdwani and {Al Shaqsi}, Laila and Ibrahim Al-Zakwani",
year = "2018",
month = "1",
day = "1",
doi = "10.5001/omj.2018.04",
language = "English",
volume = "33",
pages = "15--21",
journal = "Oman Medical Journal",
issn = "1999-768X",
publisher = "Oman Medical Specialty Board",
number = "1",

}

TY - JOUR

T1 - Neonatal and obstetrical outcomes of pregnancies in systemic lupus erythematosus

AU - Abdwani, Reem

AU - Al Shaqsi, Laila

AU - Al-Zakwani, Ibrahim

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objectives: Systemic lupus erythematous (SLE) is a chronic autoimmune disease that affects women primarily of childbearing age. The objective of this study was to determine the neonatal and maternal outcomes of pregnancies in SLE patients compared to pregnancies in healthy controls. Methods: We conducted a retrospective cohort study in a tertiary care hospital in Oman between January 2007 and December 2013. We analyzed 147 pregnancies and compared 56 (38.0%) pregnancies in women with SLE with 91 (61.9%) pregnancies in healthy control women. Disease activity was determined using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). Results: The mean age of the cohort was 30.0±5.0 years ranging from 19 to 44 years old. Patients with SLE were treated with hydroxychloroquine (n = 41; 73.2%), prednisolone (n = 38; 67.8%), and azathioprine (n = 17; 30.3%). There was no disease activity in 39.2% (n = 22) of patients while 41.0% (n = 23), 12.5% (n = 7), and 7.1% (n = 4) had mild (SLEDAI 1–5), moderate (SLEDAI 6–10), and severe (SLEDAI ≥ 11) disease activity, respectively, at onset of pregnancy. Pregnancies in patients with SLE were associated with higher abortions (42.8% vs. 15.3%; p < 0.001), gestational diabetes (28.3% vs. 10.2%; p = 0.004), polyhydramnios (7.1% vs. 0.0%; p = 0.020), previous preterm pregnancies (8.9% vs. 1.0%; p = 0.030), and intrauterine growth retardation (21.4% vs. 0.0%; p < 0.001) when compared to pregnancies in healthy control women. Furthermore, the neonates born to mothers with SLE were more likely to be preterm (28.5% vs. 1.0%; p < 0.001), have a low birth weight (< 2 500 g) (32.1% vs. 1.0%; p < 0.001), and were associated with stillbirth (7.1% vs. 0.0%; p = 0.010) when compared to neonates born to healthy control mothers. Conclusions: Pregnancies in women with SLE were associated with higher neonatal and maternal complications. Therefore, pregnant women with SLE should have their pregnancy accurately planned, monitored, and managed according to a multidisciplinary treatment schedule.

AB - Objectives: Systemic lupus erythematous (SLE) is a chronic autoimmune disease that affects women primarily of childbearing age. The objective of this study was to determine the neonatal and maternal outcomes of pregnancies in SLE patients compared to pregnancies in healthy controls. Methods: We conducted a retrospective cohort study in a tertiary care hospital in Oman between January 2007 and December 2013. We analyzed 147 pregnancies and compared 56 (38.0%) pregnancies in women with SLE with 91 (61.9%) pregnancies in healthy control women. Disease activity was determined using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). Results: The mean age of the cohort was 30.0±5.0 years ranging from 19 to 44 years old. Patients with SLE were treated with hydroxychloroquine (n = 41; 73.2%), prednisolone (n = 38; 67.8%), and azathioprine (n = 17; 30.3%). There was no disease activity in 39.2% (n = 22) of patients while 41.0% (n = 23), 12.5% (n = 7), and 7.1% (n = 4) had mild (SLEDAI 1–5), moderate (SLEDAI 6–10), and severe (SLEDAI ≥ 11) disease activity, respectively, at onset of pregnancy. Pregnancies in patients with SLE were associated with higher abortions (42.8% vs. 15.3%; p < 0.001), gestational diabetes (28.3% vs. 10.2%; p = 0.004), polyhydramnios (7.1% vs. 0.0%; p = 0.020), previous preterm pregnancies (8.9% vs. 1.0%; p = 0.030), and intrauterine growth retardation (21.4% vs. 0.0%; p < 0.001) when compared to pregnancies in healthy control women. Furthermore, the neonates born to mothers with SLE were more likely to be preterm (28.5% vs. 1.0%; p < 0.001), have a low birth weight (< 2 500 g) (32.1% vs. 1.0%; p < 0.001), and were associated with stillbirth (7.1% vs. 0.0%; p = 0.010) when compared to neonates born to healthy control mothers. Conclusions: Pregnancies in women with SLE were associated with higher neonatal and maternal complications. Therefore, pregnant women with SLE should have their pregnancy accurately planned, monitored, and managed according to a multidisciplinary treatment schedule.

KW - Intrauterine growth retardation

KW - Neonatal systemic lupus erythematosus

KW - Oman

KW - Premature infant

UR - http://www.scopus.com/inward/record.url?scp=85041896138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041896138&partnerID=8YFLogxK

U2 - 10.5001/omj.2018.04

DO - 10.5001/omj.2018.04

M3 - Article

AN - SCOPUS:85041896138

VL - 33

SP - 15

EP - 21

JO - Oman Medical Journal

JF - Oman Medical Journal

SN - 1999-768X

IS - 1

ER -